Peptide Antibiotics Market Size, Share, By Product Type (Ribosomal Synthesized Peptide Antibiotics, and Non-Ribosomal Synthesized Peptide Antibiotics), Disease (Skin Infection, HABP/VABP, Blood Stream Infection, and Others), Route of Administration (Injectable, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region - Trends, Analysis, and Forecast till 2035

Peptide antibiotics market size was valued at USD 5.3 Billion in 2025 and is expected to reach USD 8.5 Billion by 2035, growing at a CAGR of 5.3%

The family of antimicrobial medications known as peptide antibiotics, which are either naturally occurring or synthetically produced to treat bacterial infections, is composed of short chains of amino acids.

The peptide antibiotics market is driven by rising antibiotic resistance, which raises demand for novel and enhanced antimicrobial therapies. Their ability to target bacteria that are resistant to many medications, along with advancements in peptide synthesis and drug delivery technology, adds to their allure. Growing pharmaceutical R&D costs, increased awareness of hospital-acquired infections, and supportive government initiatives for the creation of innovative antibiotics are further factors propelling market expansion.